Wise Young
08-18-2002, 08:16 AM
http://library.northernlight.com/FD20020814850000100.html?cb=0&dx=1006&sc=0#doc
ViaCell Obtains Exclusive Worldwide License to Novel Protein for Use in Treatment of Stroke Recovery and Other Neurological and Neuromuscular Disorders -- Dimerized Fibroblast Growth Factor (dFGF) Shows Potential to Enhance Neurological Recovery After Stroke
------------------------------------------------------------------------
Â*
Â*Â*BOSTON, Aug 14, 2002 /PRNewswire via COMTEX/ -- ViaCell Inc., a premier cellular therapy company, announced that it has obtained an exclusive worldwide license for dimerized fibroblast growth factor (dFGF), a novel protein developed by scientists at Massachusetts Institute of Technology (M.I.T.), with applications for the treatment of stroke and other neurological disorders. ViaCell Neuroscience, a subsidiary of ViaCell, will initially develop dFGF as a product to enhance functional recovery in patients who have suffered a stroke.
ViaCell Obtains Exclusive Worldwide License to Novel Protein for Use in Treatment of Stroke Recovery and Other Neurological and Neuromuscular Disorders -- Dimerized Fibroblast Growth Factor (dFGF) Shows Potential to Enhance Neurological Recovery After Stroke
------------------------------------------------------------------------
Â*
Â*Â*BOSTON, Aug 14, 2002 /PRNewswire via COMTEX/ -- ViaCell Inc., a premier cellular therapy company, announced that it has obtained an exclusive worldwide license for dimerized fibroblast growth factor (dFGF), a novel protein developed by scientists at Massachusetts Institute of Technology (M.I.T.), with applications for the treatment of stroke and other neurological disorders. ViaCell Neuroscience, a subsidiary of ViaCell, will initially develop dFGF as a product to enhance functional recovery in patients who have suffered a stroke.